logo dark logo light logo
  • Home
  • About Us
    • Background
    • Investment Strategy
    • Team
  • Portfolio
  • News
  • Contact
  • 中文
  • Investor Login
mobile-logo
  • Home
  • About Us
    • Background
    • Investment Strategy
    • Team
  • Portfolio
  • News
  • Contact
  • 中文
  • Investor Login
We are Company Builders

We are Company Builders

Identifying, incubating and growing future industry leaders in life sciences.

We are Industry Veterans

We are Industry Veterans

Capturing evolving healthcare trends and emerging cutting-edge innovations

We are Preferred Partners

We are Preferred Partners

Connecting companies with extensive network and resources globally and in China

  • Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long- Acting Anti-TSLP Antibody WIN378

    ...

    June 9, 2026
  • OriCell’s GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma

    ...

    June 8, 2026
  • China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer

    ...

    June 8, 2026
All news

899 Halei Road, Building B, 4/F, Pudong New Area, Shanghai 201203, P.R. China
Phone: +86 21 6163 2598 | Fax: +86 21 6163 2570 | Email: info@quancapital.com

© Quan Capital. All rights reserved. Website Development. 沪ICP备18031693号-1